Compare BCBP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | INBX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.3M | 1.5B |
| IPO Year | 2005 | 2024 |
| Metric | BCBP | INBX |
|---|---|---|
| Price | $8.84 | $106.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.00 | ★ $150.00 |
| AVG Volume (30 Days) | 228.3K | ★ 322.5K |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $7.31 | $26.20 |
| 52 Week High | $11.71 | $155.29 |
| Indicator | BCBP | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 49.53 |
| Support Level | $8.50 | $96.60 |
| Resistance Level | $9.06 | $153.14 |
| Average True Range (ATR) | 0.24 | 8.00 |
| MACD | 0.06 | -2.51 |
| Stochastic Oscillator | 97.95 | 38.32 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.